Halozyme Therapeutics, Inc. (HALO) fair value analysis
Nasdaq · Updated 2026-10-19
HALO price how computed
Forward Fair Value verdict
UndervaluedHALO is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $121.84
- Sector
- Healthcare
- 12-month range
- $61.63–$121.84
- Market cap
- $13.8B
- From 52-week high
- 0.0%
- Shares outstanding
- 113M
- Rank in Healthcare by discount to fair value
- #32 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes technologies and therapeutic products focused on oncology, immunology, and other therapeutic areas. The company operates in the United States and internationally, conducting research, development, manufacturing, and sales activities across multiple regions.
HALO currently ranks #32 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $13.8B
- P/E (trailing)
- 25x
- Revenue (TTM)
- $1.66B
- Net margin
- 24.9%
- EPS (TTM)
- $4.87
- Gross margin
- 83.5%
- Debt / equity
- 14.95
- Revenue growth (3-yr avg)
- 40.9%
- Shares outstanding
- 113M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 68 · neutral
- 50-day average
- $108.92
- 200-day average
- $80.61
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-02
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+25.4%)
2026-03 ▼ miss (-30.6%)
2025-12 ▼ miss (-110.9%)
2025-09 ▲ beat (+5.5%)
2025-06 ▲ beat (+21.3%)
2025-03 ▲ beat (+16.8%)
2024-12 ▲ beat (+8.7%)
2024-09 ▲ beat (+29.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 2 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $109
- Target vs last price
- -10.5%
What our data shows for HALO
- Our model validated 17 trailing price-to-earnings windows for HALO, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $61.63–$121.84.
- The 14-day relative strength index sits at a neutral 68.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for HALO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent HALO news
TickrTrends' derived news-sentiment signal for HALO is currently leaning positive, computed from recent coverage.
- Google Cloud Outage Disrupts Services for Halifax and Revolut (gurufocus.com, 2026-10-20)
TickrTrends take: A significant Google Cloud outage that disrupted services for Halifax and Revolut highlights operational risks that extend beyond traditional tech companies into financial services and healthcare-adjacent providers. For HALO, which operates in the Healthcare sector, such infrastructure disruptions underscore the critical importance of service reliability and backup systems in maintaining business continuity and investor confidence. Given TickrTrends' current Undervalued assessment of HALO, stakeholders should monitor whether the company maintains robust contingency measures for cloud dependencies and how management communicates its resilience strategies during broader industry disruptions. - What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16 (gurufocus.com, 2026-10-20)
TickrTrends take: Tarsus Pharmaceuticals appeared prominently in First Trust NYSE Arca Biotech ETF (FBT) trading activity on October 16, which reflects institutional interest in specialty pharmaceutical names. Given that TickrTrends currently derives an Undervalued verdict for HALO, investors tracking biotech sector valuations should monitor whether similar institutional positioning extends to other healthcare companies that may share comparable valuation characteristics. ETF rebalancing and component changes can signal shifting valuations within the Healthcare sector, potentially affecting how peers like HALO are priced relative to their fundamentals. - HALO Maintained by TD Cowen -- Price Target Raised to $130 (gurufocus.com, 2026-10-13)
TickrTrends take: TD Cowen's raise of HALO's price target to $130 reflects analyst confidence in the company's fundamentals within the Healthcare sector. Given that TickrTrends currently categorizes HALO as undervalued, this analyst action suggests there may be a gap between the market's current pricing and what research professionals view as justified valuations. Valuation-focused readers should monitor whether this price target adjustment influences market perception and helps close any valuation gap identified by TickrTrends.
More HALO news
- Halozyme Therapeutics (HALO) Director Matthew Posard Sells 5,230 Shares (gurufocus.com, 2026-10-02)
- Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? (insidermonkey.com, 2026-09-21)
What people are saying
Follow the HALO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — # HALO Weekly Indicator Summary TickrTrends' derived indicators for HALO showed movement this week within the Healthcare sector. The stock's sector discount rank declined from 38 to 43, indicating a slight weakening in its relative valuation position compared to other Healthcare stocks. Despite this change, HALO maintains an undervalued verdict according to current valuation analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for HALO show that the stock's sector discount rank declined from 36 to 44 this week within the Healthcare sector. The stock maintains an Undervalued valuation verdict as of the current assessment.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is HALO stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), HALO is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is HALO's TickrTrends verdict?
HALO's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does HALO compare to other Healthcare stocks?
HALO ranks #32 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is HALO overbought or oversold?
HALO's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does HALO report earnings next?
HALO's next earnings report is scheduled for 2026-11-02, per the published earnings calendar.
Does HALO usually beat earnings estimates?
Over its last 8 reported quarters HALO beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about HALO?
Of 9 analysts covering HALO, 7 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $109 (-10.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
HALO vs BTSG · HALO vs CAI · HALO vs CI · HALO vs DVA · HALO vs EW